Abstract Number: 2711 • 2017 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T Cells Are an Important Source of TNF in Rheumatoid Arthritis
Background/Purpose: CD8+ T cells have been described to comprise up to 40% of the rheumatoid arthritis (RA) synovial T cell compartment but their pathogenic function…Abstract Number: 139 • 2017 ACR/ARHP Annual Meeting
No Effect of Tumor Necrosis Factor-a Inhibitors on Renal Function in Patients with Rheumatoid Arthritis from Kobio Registry from 2012 to 2016
Background/Purpose: Renal disease is prevalent in patients with rheumatoid arthritis (RA), although the precise prevalence of RA has not been determined. Increased mortality in patients…Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting
Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…Abstract Number: 515 • 2017 ACR/ARHP Annual Meeting
Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy
- Background/Purpose: Tumor necrosis factor (TNF) alpha, a key proinflammatory cytokine in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), has been a major target in…Abstract Number: 959 • 2017 ACR/ARHP Annual Meeting
A Disintegrin and Metalloprotease -17 Is Overexpressed on Rheumatoid Arthritis Osteoblasts and Is Regulated with TNF-α Stimulation
Background/Purpose: A disintegrin and metalloprotease family proteins (ADAMs) have been reported to be involved in a number of inflammatory conditions. We have previously reported a…Abstract Number: 973 • 2017 ACR/ARHP Annual Meeting
IL-6 and TNF-a Cooperate to Modulate the Cell Cycle of RA-Fibroblast-like Synoviocytes Via Cyclin Dependent Kinase Inhibitors
Background/Purpose: IL-6 and TNF-α play an important role in the pathogenesis of RA, and the proliferation of RA-synoviocytes (FLS) is controlled by cell cycle regulators…Abstract Number: 1036 • 2017 ACR/ARHP Annual Meeting
Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Background/Purpose: There is evidence linking activation of the innate immune system and insulin resistance. Perturbations in glucose homeostasis upon initiation of tumor-necrosis factor inhibitors (TNFis)…Abstract Number: 1415 • 2017 ACR/ARHP Annual Meeting
TNF-Induced IRF1 Is Critical for the Inflammatory Gene Expression in Fibroblast-like Synoviocytes
Background/Purpose: Fibroblast-like synoviocytes (FLS) are increasingly recognised as major pathogenic cells in synovial inflammation of patients with Rheumatoid Arthritis (RA). In response to pro-inflammatory stimuli,…Abstract Number: 1428 • 2017 ACR/ARHP Annual Meeting
Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Background/Purpose: Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and…Abstract Number: 1433 • 2017 ACR/ARHP Annual Meeting
Tailoring Second-Line Biologic Therapy in Rheumatoid Arthritis: New Findings on the Usefulness of Antibody Status to Optimise Drug Selection
Background/Purpose: Treatment of rheumatoid arthritis (RA) has been revolutionized by the introduction of Tumour Necrosis Factor alpha inhibitors (TNFi). However a significant proportion of patients…Abstract Number: 1791 • 2017 ACR/ARHP Annual Meeting
TET1 Is an Important Transcriptional Activator of the Tnfa Locus in Macrophages
Background/Purpose: Activated macrophages are found in the inflamed and hyperplastic synovial RA tissue. Macrophages are the main producers of high levels of pro-inflammatory cytokines such…Abstract Number: 1817 • 2017 ACR/ARHP Annual Meeting
Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry
Background/Purpose: In the absence of biomarkers predicting response to a specific therapy, the choice of second biologic is based mostly on habit and availability of…Abstract Number: 2533 • 2016 ACR/ARHP Annual Meeting
Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?
Background/Purpose: Rheumatoid arthritis (RA) patients frequently report concomitant comorbidities that could worsen their prognosis. Tumor necrosis factor inhibitors (TNFi), the most common biological agents used,…Abstract Number: 2651 • 2016 ACR/ARHP Annual Meeting
Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate: a Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab
Background/Purpose: Methotrexate (MTX) is recommended as first-line therapy in patients (pts) with rheumatoid arthritis (RA).1 However, information is limited regarding factors that may predict a…Abstract Number: 3012 • 2016 ACR/ARHP Annual Meeting
Clinical Predictors of TNF-Inhibitor Free Disease Control in Patients with Rheumatoid Arthritis after Stopping TNFi Treatment: Results from a Dutch Multicentre Pragmatic Open-Label Randomized Controlled Trial.
Background/Purpose: Tumor Necrosis Factor inhibitor (TNFi) free prolonged acceptable disease control in patients with rheumatoid arthritis (RA), in stable remission or low disease activity…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »